Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
239 hedge funds and large institutions have $2.91B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2018 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 81 increasing their positions, 75 reducing their positions, and 34 closing their positions.
111% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $9.21M
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
56% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 34
8% more funds holding
Funds holding: 221 → 239 (+18)
8% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 75
2% less capital invested
Capital invested by funds: $2.98B → $2.91B (-$63.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.1M |
| 2 |
D.E. Shaw & Co
New York
|
+$25.7M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$18.4M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$17.4M |
| 5 |
Jennison Associates
New York
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$79.1M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$77M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$21.4M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$19.4M |
| 5 |
Morgan Stanley
New York
|
-$10.9M |
HZNP Hedge Fund Activity: Q4 2018 in Review
239 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2018, worth a combined $2.91B — down 2.1% from $2.98B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new HZNP positions and 34 closed out — a net gain of 19 holders — while 81 added to existing stakes and 75 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $30.1M. The largest seller was Scopia Capital Management, cutting an estimated $79.1M.
- 239 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2018, up from 221 in Q3 2018.
- Funds reported $2.91B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2018, down 2.1% quarter-over-quarter.
- 53 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2018 and 34 closed out, a net change of +19 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2018 was Fidelity Investments, an estimated $30.1M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2018 was Scopia Capital Management, an estimated $79.1M sold.
Based on aggregated 13F filings for Q4 2018.